结果公布-话题@MedSci

#结果公布#

126篇内容 | 3404人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2004424, encodeId=b18220044246e, content=<a href='/topic/show?id=54ebe8621cf' target=_blank style='color:#2F92EE;'>#结果公布#</a>, objectTitle=ADAURA III期临床研究结果公布：奥希替尼治疗中枢神经系统转移可改善无病生存期, objectType=article, longId=201090, objectId=24af2010905f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=24af2010905f, replyNumber=0, likeNumber=49, createdTime=2021-02-02, rootId=0, userName=shanyongle, userId=279b407, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=24af2010905f, moduleTitle=ADAURA III期临床研究结果公布：奥希替尼治疗中枢神经系统转移可改善无病生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=24af2010905f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2004423, encodeId=2755200442341, content=<a href='/topic/show?id=54ebe8621cf' target=_blank style='color:#2F92EE;'>#结果公布#</a>, objectTitle=EXCEL研究5年结果公布，CABG和PCI孰优孰劣？, objectType=article, longId=198027, objectId=21c919802e28, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=21c919802e28, replyNumber=0, likeNumber=0, createdTime=2021-01-04, rootId=0, userName=shanyongle, userId=279b407, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=21c919802e28, moduleTitle=EXCEL研究5年结果公布，CABG和PCI孰优孰劣？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=21c919802e28)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2004427, encodeId=5f89200442ec0, content=<a href='/topic/show?id=54ebe8621cf' target=_blank style='color:#2F92EE;'>#结果公布#</a>, objectTitle=ASCO GU 2021: 免疫联合靶向在晚期肾癌中大获成功，完成2年治疗的人群结果公布（KEYNOTE-426研究）, objectType=article, longId=207203, objectId=134820e203ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=134820e203ba, replyNumber=0, likeNumber=84, createdTime=2021-09-28, rootId=0, userName=shanyongle, userId=279b407, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=134820e203ba, moduleTitle=ASCO GU 2021: 免疫联合靶向在晚期肾癌中大获成功，完成2年治疗的人群结果公布（KEYNOTE-426研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=134820e203ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2004420, encodeId=15b3200442027, content=<a href='/topic/show?id=54ebe8621cf' target=_blank style='color:#2F92EE;'>#结果公布#</a>, objectTitle=OCC 2020 | 伊伐布雷定改善心衰患者症状、心功能和生活质量！POSITIVE研究期中分析结果公布, objectType=article, longId=195385, objectId=e0ca19538516, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e0ca19538516, replyNumber=0, likeNumber=58, createdTime=2020-08-20, rootId=0, userName=shanyongle, userId=279b407, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e0ca19538516, moduleTitle=OCC 2020 | 伊伐布雷定改善心衰患者症状、心功能和生活质量！POSITIVE研究期中分析结果公布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e0ca19538516)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2004411, encodeId=6b992004411f0, content=<a href='/topic/show?id=54ebe8621cf' target=_blank style='color:#2F92EE;'>#结果公布#</a>, objectTitle=AACR 2020：豪森药业阿美替尼用于EGFR突变耐药的NSCLC患者结果公布, objectType=article, longId=193108, objectId=28561931082d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=28561931082d, replyNumber=0, likeNumber=80, createdTime=2020-12-16, rootId=0, userName=shanyongle, userId=279b407, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=28561931082d, moduleTitle=AACR 2020：豪森药业阿美替尼用于EGFR突变耐药的NSCLC患者结果公布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=28561931082d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2004410, encodeId=c86b2004410d5, content=<a href='/topic/show?id=54ebe8621cf' target=_blank style='color:#2F92EE;'>#结果公布#</a>, objectTitle=带量采购中标结果公布，154个品种大降价, objectType=article, longId=192439, objectId=78e0192439c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=78e0192439c0, replyNumber=0, likeNumber=71, createdTime=2020-06-11, rootId=0, userName=shanyongle, userId=279b407, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=78e0192439c0, moduleTitle=带量采购中标结果公布，154个品种大降价, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=78e0192439c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2004413, encodeId=a2c72004413ea, content=<a href='/topic/show?id=54ebe8621cf' target=_blank style='color:#2F92EE;'>#结果公布#</a>, objectTitle=AACR 2020：CAR-T治疗复发性或难治性(R/R)急性T淋巴细胞白血病试验初步结果公布, objectType=article, longId=193184, objectId=fb6d193184c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fb6d193184c5, replyNumber=0, likeNumber=110, createdTime=2021-03-19, rootId=0, userName=shanyongle, userId=279b407, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fb6d193184c5, moduleTitle=AACR 2020：CAR-T治疗复发性或难治性(R/R)急性T淋巴细胞白血病试验初步结果公布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fb6d193184c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2004421, encodeId=122b200442152, content=<a href='/topic/show?id=54ebe8621cf' target=_blank style='color:#2F92EE;'>#结果公布#</a>, objectTitle=22个药，带量采购结果公布, objectType=article, longId=196140, objectId=e5c019614006, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e5c019614006, replyNumber=0, likeNumber=77, createdTime=2021-05-17, rootId=0, userName=shanyongle, userId=279b407, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e5c019614006, moduleTitle=22个药，带量采购结果公布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e5c019614006)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2004422, encodeId=c59e200442209, content=<a href='/topic/show?id=54ebe8621cf' target=_blank style='color:#2F92EE;'>#结果公布#</a>, objectTitle=CheckMate-870结果公布：欧狄沃240毫克固定剂量30分钟输注在以中国人群为主的经治晚期或转移性NSCLC患者中安全可靠, objectType=article, longId=196839, objectId=69e81968399f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=69e81968399f, replyNumber=0, likeNumber=66, createdTime=2020-07-18, rootId=0, userName=shanyongle, userId=279b407, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=69e81968399f, moduleTitle=CheckMate-870结果公布：欧狄沃240毫克固定剂量30分钟输注在以中国人群为主的经治晚期或转移性NSCLC患者中安全可靠, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=69e81968399f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2004417, encodeId=6fd4200441e28, content=<a href='/topic/show?id=54ebe8621cf' target=_blank style='color:#2F92EE;'>#结果公布#</a>, objectTitle=Lancet：陈薇院士新冠疫苗1期临床试验结果公布，108名志愿者全部产生免疫应答！, objectType=article, longId=194622, objectId=3cc61946226d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3cc61946226d, replyNumber=0, likeNumber=47, createdTime=2020-09-24, rootId=0, userName=shanyongle, userId=279b407, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3cc61946226d, moduleTitle=Lancet：陈薇院士新冠疫苗1期临床试验结果公布，108名志愿者全部产生免疫应答！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3cc61946226d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2004419, encodeId=2bda20044198a, content=<a href='/topic/show?id=54ebe8621cf' target=_blank style='color:#2F92EE;'>#结果公布#</a>, objectTitle=2020年国家自然科学基金项目初审结果公布, objectType=article, longId=195366, objectId=fe7f195366de, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fe7f195366de, replyNumber=0, likeNumber=63, createdTime=2020-06-11, rootId=0, userName=shanyongle, userId=279b407, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fe7f195366de, moduleTitle=2020年国家自然科学基金项目初审结果公布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fe7f195366de)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2004414, encodeId=712d2004414c9, content=<a href='/topic/show?id=54ebe8621cf' target=_blank style='color:#2F92EE;'>#结果公布#</a>, objectTitle=AACR 2020：索凡替尼联合特瑞普利单抗治疗晚期实体瘤Ⅰ期研究结果公布, objectType=article, longId=193342, objectId=4e5d193342f4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e5d193342f4, replyNumber=0, likeNumber=57, createdTime=2020-07-04, rootId=0, userName=shanyongle, userId=279b407, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e5d193342f4, moduleTitle=AACR 2020：索凡替尼联合特瑞普利单抗治疗晚期实体瘤Ⅰ期研究结果公布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4e5d193342f4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2004418, encodeId=91282004418f4, content=<a href='/topic/show?id=54ebe8621cf' target=_blank style='color:#2F92EE;'>#结果公布#</a>, objectTitle=Lancet：羟基氯喹/氯喹治疗COVID-19结果公布：降低生存率！, objectType=article, longId=194624, objectId=1c2a19462414, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1c2a19462414, replyNumber=0, likeNumber=74, createdTime=2020-05-27, rootId=0, userName=shanyongle, userId=279b407, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1c2a19462414, moduleTitle=Lancet：羟基氯喹/氯喹治疗COVID-19结果公布：降低生存率！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1c2a19462414)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2004412, encodeId=27462004412c7, content=<a href='/topic/show?id=54ebe8621cf' target=_blank style='color:#2F92EE;'>#结果公布#</a>, objectTitle=AACR 2020：KRAS新药用于NSCLC结果公布, objectType=article, longId=193182, objectId=863c19318287, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=863c19318287, replyNumber=0, likeNumber=63, createdTime=2020-06-21, rootId=0, userName=shanyongle, userId=279b407, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=863c19318287, moduleTitle=AACR 2020：KRAS新药用于NSCLC结果公布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=863c19318287)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2004409, encodeId=63b6200440912, content=<a href='/topic/show?id=54ebe8621cf' target=_blank style='color:#2F92EE;'>#结果公布#</a>, objectTitle=NEJM：重磅！雷地西韦治疗重症Covid-19患者临床结果公布, objectType=article, longId=192014, objectId=e0d41920140e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e0d41920140e, replyNumber=0, likeNumber=70, createdTime=2020-06-01, rootId=0, userName=shanyongle, userId=279b407, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e0d41920140e, moduleTitle=NEJM：重磅！雷地西韦治疗重症Covid-19患者临床结果公布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e0d41920140e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2004415, encodeId=b7522004415ca, content=<a href='/topic/show?id=54ebe8621cf' target=_blank style='color:#2F92EE;'>#结果公布#</a>, objectTitle=Clin Cancer Res：科济生物靶向GPC3的CAR-T细胞治疗晚期肝细胞癌的1期结果公布，初步取得显著疗效, objectType=article, longId=194140, objectId=8189194140e6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8189194140e6, replyNumber=0, likeNumber=55, createdTime=2020-07-07, rootId=0, userName=shanyongle, userId=279b407, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8189194140e6, moduleTitle=Clin Cancer Res：科济生物靶向GPC3的CAR-T细胞治疗晚期肝细胞癌的1期结果公布，初步取得显著疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8189194140e6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2004416, encodeId=3656200441665, content=<a href='/topic/show?id=54ebe8621cf' target=_blank style='color:#2F92EE;'>#结果公布#</a>, objectTitle=Lancet Oncol：卡瑞利珠单抗二线治疗食管癌 III 期研究结果公布，患者死亡风险减少三成（ESCORT试验）, objectType=article, longId=194143, objectId=2d2a194143a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2d2a194143a2, replyNumber=0, likeNumber=0, createdTime=2020-08-28, rootId=0, userName=shanyongle, userId=279b407, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2d2a194143a2, moduleTitle=Lancet Oncol：卡瑞利珠单抗二线治疗食管癌 III 期研究结果公布，患者死亡风险减少三成（ESCORT试验）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2d2a194143a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2004408, encodeId=40bc200440810, content=<a href='/topic/show?id=54ebe8621cf' target=_blank style='color:#2F92EE;'>#结果公布#</a>, objectTitle=中国心脏医生的高血压情况，中国2441医院近3万心脏医生调查结果公布, objectType=article, longId=181075, objectId=270b1810e53d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=270b1810e53d, replyNumber=0, likeNumber=61, createdTime=2020-06-26, rootId=0, userName=shanyongle, userId=279b407, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=270b1810e53d, moduleTitle=中国心脏医生的高血压情况，中国2441医院近3万心脏医生调查结果公布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=270b1810e53d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2004407, encodeId=cfe3200440efd, content=<a href='/topic/show?id=54ebe8621cf' target=_blank style='color:#2F92EE;'>#结果公布#</a>, objectTitle=【奖项公布】梅斯医学2019研究方案评选大赛结果公布啦！, objectType=article, longId=180665, objectId=e7e61806653c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e7e61806653c, replyNumber=0, likeNumber=72, createdTime=2019-11-07, rootId=0, userName=shanyongle, userId=279b407, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e7e61806653c, moduleTitle=【奖项公布】梅斯医学2019研究方案评选大赛结果公布啦！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e7e61806653c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2004406, encodeId=5a1b200440646, content=<a href='/topic/show?id=54ebe8621cf' target=_blank style='color:#2F92EE;'>#结果公布#</a>, objectTitle=EASD2019 | 重磅！VERIFY研究结果公布：早期联合可显著减少T2DM起始治疗失败相对风险49%, objectType=article, longId=179885, objectId=c33d1e9885d7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c33d1e9885d7, replyNumber=0, likeNumber=96, createdTime=2020-07-25, rootId=0, userName=shanyongle, userId=279b407, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c33d1e9885d7, moduleTitle=EASD2019 | 重磅！VERIFY研究结果公布：早期联合可显著减少T2DM起始治疗失败相对风险49%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c33d1e9885d7)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

结果公布

2020-05-29

shanyongle (审核中...)

前往app查看评论内容

#结果公布#

ADAURA III期临床研究结果公布：奥希替尼治疗中枢神经系统转移可改善无病生存期

2021-02-02

shanyongle (审核中...)

前往app查看评论内容

#结果公布#

EXCEL研究5年结果公布，CABG和PCI孰优孰劣？

2021-01-04

shanyongle (审核中...)

前往app查看评论内容

#结果公布#

ASCO GU 2021: 免疫联合靶向在晚期肾癌中大获成功，完成2年治疗的人群结果公布（KEYNOTE-426研究）

2021-09-28

shanyongle (审核中...)

前往app查看评论内容

#结果公布#

OCC 2020 | 伊伐布雷定改善心衰患者症状、心功能和生活质量！POSITIVE研究期中分析结果公布

2020-08-20

shanyongle (审核中...)

前往app查看评论内容

#结果公布#

AACR 2020：豪森药业阿美替尼用于EGFR突变耐药的NSCLC患者结果公布

2020-12-16

shanyongle (审核中...)

前往app查看评论内容

#结果公布#

带量采购中标结果公布，154个品种大降价

2020-06-11

shanyongle (审核中...)

前往app查看评论内容

#结果公布#

AACR 2020：CAR-T治疗复发性或难治性(R/R)急性T淋巴细胞白血病试验初步结果公布

2021-03-19

shanyongle (审核中...)

前往app查看评论内容

#结果公布#

22个药，带量采购结果公布

2021-05-17

shanyongle (审核中...)

前往app查看评论内容

#结果公布#

CheckMate-870结果公布：欧狄沃240毫克固定剂量30分钟输注在以中国人群为主的经治晚期或转移性NSCLC患者中安全可靠

2020-07-18

shanyongle (审核中...)

前往app查看评论内容

#结果公布#

Lancet：陈薇院士新冠疫苗1期临床试验结果公布，108名志愿者全部产生免疫应答！

2020-09-24

shanyongle (审核中...)

前往app查看评论内容

#结果公布#

2020年国家自然科学基金项目初审结果公布

2020-06-11

shanyongle (审核中...)

前往app查看评论内容

#结果公布#

AACR 2020：索凡替尼联合特瑞普利单抗治疗晚期实体瘤Ⅰ期研究结果公布

2020-07-04

shanyongle (审核中...)

前往app查看评论内容

#结果公布#

Lancet：羟基氯喹/氯喹治疗COVID-19结果公布：降低生存率！

2020-05-27

shanyongle (审核中...)

前往app查看评论内容

#结果公布#

AACR 2020：KRAS新药用于NSCLC结果公布

2020-06-21

shanyongle (审核中...)

前往app查看评论内容

#结果公布#

NEJM：重磅！雷地西韦治疗重症Covid-19患者临床结果公布

2020-06-01

shanyongle (审核中...)

前往app查看评论内容

#结果公布#

Clin Cancer Res：科济生物靶向GPC3的CAR-T细胞治疗晚期肝细胞癌的1期结果公布，初步取得显著疗效

2020-07-07

shanyongle (审核中...)

前往app查看评论内容

#结果公布#

Lancet Oncol：卡瑞利珠单抗二线治疗食管癌 III 期研究结果公布，患者死亡风险减少三成（ESCORT试验）

2020-08-28

shanyongle (审核中...)

前往app查看评论内容

#结果公布#

中国心脏医生的高血压情况，中国2441医院近3万心脏医生调查结果公布

2020-06-26

shanyongle (审核中...)

前往app查看评论内容

#结果公布#

【奖项公布】梅斯医学2019研究方案评选大赛结果公布啦！

2019-11-07

shanyongle (审核中...)

前往app查看评论内容

#结果公布#

EASD2019 | 重磅！VERIFY研究结果公布：早期联合可显著减少T2DM起始治疗失败相对风险49%

2020-07-25

科室
- - 订阅+
  - 更多科室
工具
服务